Successful treatment of pulmonary Mycobacterium xenopi infection in a natural killer cell-deficient patient with clarithromycin, rifabutin, and sparfloxacin

Clinical Infectious Diseases

Volumn 29, Issue 1, 1999, Pages 120-124

  Schmitt, Hans ^a   Schnitzler, Norbert ^a   Riehl, Jochen ^a   Adam, Gerhard ^a   Sieberth, Heinz Günter ^a   Haase, Gerhard ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; RIFABUTIN; SPARFLOXACIN;

ADULT; ARTICLE; BACTERIAL PNEUMONIA; BACTERIUM ISOLATION; CASE REPORT; CONTROLLED STUDY; DRUG MIXTURE; HUMAN; IMMUNE DEFICIENCY; LUNG TUBERCULOSIS; MALE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM XENOPEI; NATURAL KILLER CELL; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL;

EID: 0032771410     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520140     Document Type: Article

References (63)

1. 1. American Thoracic Society. Diagnosis and treatment of disease caused by non-tuberculous mycobacteria. Am J Respir Crit Care Med 1997;156(suppl):S1-25.
2. 2. Woods GL, Washington JA. Mycobacteria other than Mycobacterium tuberculosis: review of microbiologic and clinical aspects. Rev Infect Dis 1987;9:275-94.
3. 3. Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis 1979;119:107-59.
4. 4. Wayne LG, Sramek HA. Agents of newly recognized or infrequently encountered mycobacterial diseases. Clin Microbiol Rev 1992;5:1-25.
5. 5. Jiva TM, Jacoby HM, Weymouth LA, Kaminski DA, Portmore AC. Mycobacterium xenopi: innocent bystander or emerging pathogen? Clin Infect Dis 1997;24:226-32.
6. 6. Wolinsky E. Editorial response: is Mycobacterium xenopi an emerging pathogen? Clin Infect Dis 1997;24:233-4.
7. 7. Costrini AM, Mahler DA, Gross WM, et al. Clinical and roentgenographic features of nosocomial pulmonary disease due to Mycobacterium xenopi. Am Rev Respir Dis 1981;123:104-9.
8. 8. Yuen K, Fam AG, Simor A. Mycobacterium xenopi arthritis. J Rheumatol 1998;25:1016-8.
9. 9. Jacoby HM, Jiva TM, Kaminski DA, Weymouth LA, Portmore AC. Mycobacterium xenopi infection masquerading as pulmonary tuberculosis in two patients infected with the human immunodeficiency virus. Clin Infect Dis 1995;20:1399-401.
10. 10. Banks J, Hunter AM, Campbell IA, Jenkins PA, Smith AP. Pulmonary infection with Mycobacterium xenopi: review of treatment and response. Thorax 1984;39:376-82.
11. 11. Smith MJ, Citron KM. Clinical review of pulmonary disease caused by Mycobacterium xenopi. Thorax 1983;38:373-7.
12. 12. Bogaerts Y, Elinck W, van Renterghem D, Pauwels R, van der Straeten M. Pulmonary disease due to Mycobacterium xenopi: report of two cases. Eur J Respir Dis 1982;63:298-304.
13. 13. Koizumi JH, Sommers HM. Mycobacterium xenopi and pulmonary disease. Am J Clin Pathol 1980;73:826-30.
14. 14. Simor AE, Salit IE, Vellend H. The role of Mycobacterium xenopi in human disease. Am Rev Respir Dis 1984;129:435-8.
15. 15. Contreras MA, Cheung OT, Sanders DE, Goldstein RS. Pulmonary infection with nontuberculous mycobacteria. Am Rev Respir Dis 1988;137:149-52.
16. 16. Terashima T, Sakamaki F, Hasegawa N, Kanazawa M, Kawashiro T. Pulmonary infection due to Mycobacterium xenopi. Int Med 1994;33:536-9.
17. 17. Wittram C, Weisbrod GL. Mycobacterium xenopi pulmonary infection: evaluation with CT. J Comput Assist Tomogr 1998;22:225-8.
18. 18. Shafer RW, Sierra MF. Mycobacterium xenopi, Mycobacterium fortuitum, Mycobacterium kansasii, and other nontuberculous mycobacteria in an area of endemicity for AIDS. Clin Infect Dis 1992;15:161-2.
19. 19. Tenholder MF, Moser RJ, Telli CJ. Mycobacteria other than tuberculosis: pulmonary involvement in patients with acquired immunodeficiency syndrome. Arch Intern Med 1988;148:953-5.
20. 20. Ausina V, Barrio J, Luquin M, Sambeat MA, et al. Mycobacterium xenopi infections in the acquired immunodeficiency syndrome. Ann Intern Med 1988;108:927-8.
21. 21. Lichtenstein IH, MacGregor RR. Mycobacterial infections in renal transplant recipients: report of five cases and review of the literature. Rev Infect Dis 1983;5:216-26.
22. 22. Weber J, Mettang T, Staerz E, Machleidt C, Kuhlmann U. Pulmonary disease due to Mycobacterium xenopi in a renal allograft recipient: report of a case and review. Rev Infect Dis 1989;6:964-9.
23. 23. Branger R, Gouby A, Oulês R, Balducchi JP, et al. Mycobacterium haemophilum and Mycobacterium xenopi associated infection in a renal transplant patient. Clin Nephrol 1985;23:46-9.
24. 24. Damsker B, Bottone EJ, Deligdisch L. Mycobacterium xenopi: infection in an immunocompromised host. Hum Pathol 1982;13:866-70.
25. 25. el-Helou P, Rachlis A, Fong I, Walmsley S, Phillips A, Salit I, Simor AE. Mycobacterium xenopi infections in patients with human immunodeficiency virus infection. Clin Infect Dis 1997;25:206-10.
26. 26. De Coster C, Verstraeten JM, Dumortier P, De Vuyst P. Atypical mycobacteriosis as a complication of talc pneumoconiosis. Eur Respir J 1996;9:1757-9.
27. 27. Weinberg JR, Dootson G, Gertner D, Chambers ST, Smith H. Disseminated Mycobacterium xenopi infection. Lancet 1985;1:1033-4.
28. 28. Price AB, Owen R, Sowter G, Weinberg J, Smith H. Disseminated Mycobacterium xenopi infection [letter]. Lancet 1985;2:383.
29. 29. Kirschner PB, Springer B, Vogel A, et al. Genotypic identification of mycobacteria by nucleic acid sequence determination: report of a 2-year experience in a clinical laboratory. J Clin Microbiol 1993;31:2882-9.
30. 30. Takewaki S, Okuzumi K, Manabe I, et al. Nucleotide sequence comparison of the mycobacterial dnaJ gene and PCR restriction fragment length polymorphism analysis for identification of mycobacterial species. Int J Syst Bacteriol 1994;44:159-66.
31. 31. Zurawski CA, Cage GD, Rimland D, Blumberg HM. Pneumonia and bacteremia due to Mycobacterium celatum masquerading as Mycobacterium xenopi in patients with AIDS: an underdiagnosed problem? Clin Infect Dis 1997;24:140-3.
32. 32. Parrot RG, Grosset JH. Post-surgical outcome of 57 patients with Mycobacterium xenopi pulmonary infection. Tubercle 1978;69:47-55.
33. 33. Wallace RJ Jr, Brown BA, Onyi GO. Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis 1992;166:405-12.
34. 34. Flesch I, Kaufmann SHE. Activation of tuberculostatic macrophage functions by interferon-γ, interleukin 4 and tumor necrosis factor. Infect Immun 1990;58:2675-7.
35. 35. Kaufmann SHE. Immunity to intracellular bacteria. Annu Rev Immunol 1993;11:129-63.
36. 36. Orme IM, Andersen P, Boom WH. T cell response to Mycobacterium tuberculosis. J Infect Dis 1993;167:1481-97.
37. 37. Bothamley GH, Festenstein F, Newland A. Protective role of CD8 cells in tuberculosis. Lancet 1992;339:315-6.
38. 38. Flynn JL, Goldstein MM, Triebold KJ, et al. Major histocompatibility complex class-I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 1992;89:12013-7.
39. 39. Orme IM. The kinetics of emergence and loss of mediator T lymphocytes acquired in response to infection with Mycobacterium tuberculosis. J Immunol 1987;138:293-8.
40. 40. Orme IM, Miller ES, Roberts AD, et al. T lymphocytes mediating protection and cellular cytolysis during the course of Mycobacterium tuberculosis infection. J Immunol 1992;148:189-96.
41. 41. Kaufmann SHE. CD8+ T lymphocytes in intracellular microbial infections. Immunol Today 1988;9:168-74.
42. 42. Smith D, Hansch H, Bancroft G, et al. T-cell-independent granuloma formation in response to Mycobacterium avium: role of tumour necrosis factor-alpha and interferon-gamma. Immunology 1997;92:413-21.
43. 43. van Ierssel GJHM, van der Sluys-Veer A, Verspaget HW, Griffioen G, van Hogezand RA, Lamers CBHW. Contribution of plasma cortisol to corticosteroid-suppressed peripheral blood natural killer cell activity in Crohn's disease. Immunopharmacology 1995;29:11-7.
44. 44. Zhou J, Olsen S, Moldovan J, et al. Glucocorticoid regulation of natural cytotoxicity: effects of cortisol on the phenotype and function of a cloned human natural killer cell line. Cell Immunol 1997;178:108-16.
45. 45. Jouveshomme S, Dautzenberg B, Bakdach H, Derenne JP. Preliminary results of collapse therapy with plombage for pulmonary disease caused by multidrug-resistant mycobactoria. Am J Respir Crit Care Med 1998;157:1609-15.
46. 46. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996;335:384-91.
47. 47. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996;335:392-8.
48. 48. Shafran SD, Singer J, Zarowny DP, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethampin, ethambutol, clofazimine, and ciprofloxacin. N Engl J Med 1996;335:377-83.
49. 49. Koletar SL. Treatment of Mycobacterium avium in human immunodeficiency virus-infected individuals. Am J Med 1997;102:16-21.
50. 50. Amsden GW, Peloquin CA, Berning SE. The role of advanced generation macrolides in the prophylaxis and treatment of Mycobacterium avium complex (MAC) infections. Drugs 1997;54:69-80.
51. 51. Hardly DJ. Extent and spectrum of the antimicrobial activity of clarithromycin. Pediatr Infect Dis J 1993;12(suppl 3):S99-105.
52. 52. Dautzenberg B, Papillon F, Lepitre M, Truffot-Pernod CH, Chauvin JP. Mycobacterium xenopi infections treated with clarithromycin containing regimens [abstract no 1125]. In: Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1993:417.
53. 53. Gevaudan MJ, Bollet C, Mallet MN, Gulian G, Tissot-Dupont H, de Micco P. Etude de l'activité de l'azithromycine et de la roxithromycine seules et en associations vis-a-vis de Mycobacterium avium et Mycobacterium xenopi. Pathol Biol 1990;38:413-9.
54. 54. Piersimoni C, Tortoli E, Mascellino MT, et al. Activity of seven antimicrobial agents, alone and in combination, against AIDS-associated isolates of Mycobacterium avium complex. J Antimicrob Chemother 1995;36:497-502.
55. 55. Rastogi N, Bauriaud RM, Bourgoin A, et al. French multicenter study involving eight test sites for radiometric determination of activities of 10 antimicrobial agents against Mycobacterium avium complex. Antimicrob Agents Chemother 1995;39:6138-44.
56. 56. Sanchez-Carillo C, Cotarelo M, Cercenado E, Vincente T, Blazquez R, Bouza E. Comparative in vitro activity of sparfloxacin and eight other antimicrobial agents against clinical isolates of non-tuberculous mycobacteria. J Antimicrob Chemother 1996;37:151-4.
57. 57. Martin-Luengo F, Sempere M. Activity of sparfloxacin and other quinolones against mycobacteria. Drugs 1993;45(suppl 3):219-20.
58. 58. Gevaudan MJ, Bollet C, Mallet MN, et al. Extracellular and intracellular activities of sparfloxacin against Mycobacterium avium complex and Mycobacterium xenopi. Pathol Biol 1992;40:443-9.
59. 59. Truffot-Pernot C, Ji B, Grosset J. In vitro activity of sparfloxacin against tuberculous and non-tuberculous mycobacteria. Eur J Clin Microbiol Infect Dis 1991;Special issue:561-2.
60. 60. Garcia-Rodriguez JA, Garcia ACG. In vitro activities of quinolones against mycobacteria. J Antimicrob Chemother 1993;32:797-808.
61. 61. Rastogi N, Goh KS, Bryskier A, Devallois A. Spectrum of activity of levufloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine. Antimicrob Agents Chemother 1996;40:2483-7.
62. 62. Alangaden GJ, Lerner SA. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis 1997;25:1213-21.
63. 63. Roche B, Rozenberg S, Cambau E, Desplaces N, et al. Efficacy of combined clarithromycin and sparfloxacin therapy in a patient with discilis due to Mycobacterium xenopi [letter]. Rev Rhum Engl Ed 1997;64:64-5.